Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells
- 31 May 2013
- journal article
- Published by Elsevier BV in Pharmacological Research
- Vol. 71, 23-33
- https://doi.org/10.1016/j.phrs.2013.02.001
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Science and Technology (MEST-2010-0022674)
- National Institutes of Health (CA114425-06, P50-CA098252)
- National Research Foundation of Korea
This publication has 50 references indexed in Scilit:
- Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial PathwayClinical Cancer Research, 2011
- Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell deathMolecular Cancer Therapeutics, 2009
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinThe Journal of Experimental Medicine, 2008
- Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccinationJournal of Molecular Medicine, 2008
- Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune EvasionCancer Research, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cellsApoptosis, 2006
- Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylationProceedings of the National Academy of Sciences of the United States of America, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Stat proteins and oncogenesisJCI Insight, 2002